In-Depth Market Analysis On Hepatitis C - Pipeline Review, H2 2016
Hepatitis C - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Hepatitis C (Infectious Disease) pipeline landscape.
Hepatitis C is a contagious viral infection affecting the liver. It may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea and vomiting The predisposing factors of hepatitis C include dialysis, organ transplant and blood transfusion. Offspring of an infected mother also has high chances of contracting the disease. Hepatitis C can be controlled with the help of medications or a transplant at an advanced stage.
Complete report available @ Hepatitis C - Pipeline Review, H2 2016
Report Highlights
This report provides comprehensive information on the therapeutics under development for Hepatitis C (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hepatitis C (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 15, 33, 19, 1, 56, 41 and 4 respectively for Similarly, the Universities portfolio in Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 2, 1, 9 and 24 molecules, respectively for Hepatitis C.
Hepatitis C (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis C (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Hepatitis C (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hepatitis C (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hepatitis C (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis C (Infectious Disease)
- The pipeline guide reviews pipeline therapeutics for Hepatitis C (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hepatitis C (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hepatitis C (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis C (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hepatitis C (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hepatitis C (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hepatitis C (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hepatitis C (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
3-V Biosciences, Inc. AbbVie Inc AIMM Therapeutics B.V. Akshaya Bio Inc. Amarillo Biosciences, Inc. Amarna Therapeutics B.V. ARA Healthcare Pvt. Ltd. Aviragen Therapeutics, Inc. Beijing Kawin Technology Share-Holding Co., Ltd. Benitec Biopharma Limited Beta Pharma, Inc. Biogenomics Limited BioLineRx, Ltd. Bionor Pharma ASA Biotest AG Biotron Limited Boehringer Ingelheim GmbH Bolder Biotechnology, Inc. Bristol-Myers Squibb Company Chugai Pharmaceutical Co., Ltd. Cocrystal Pharma, Inc. Conatus Pharmaceuticals Inc. ContraVir Pharmaceuticals, Inc. DEKK-TEC, Inc. Delpor, Inc. Digna Biotech, S.L. Enanta Pharmaceuticals, Inc. F. Hoffmann-La Roche Ltd. Formune S.L. Genecode AS GeneCure LLC Gilead Sciences, Inc. GinkgoPharma Co. Ltd. GlaxoSmithKline Plc HanAll Biopharma Co., Ltd. HEC Pharm Co., Ltd. ImmunoBiology Limited Inovio Pharmaceuticals, Inc. Integrated BioTherapeutics, Inc. JN-International Medical Corporation Johnson & Johnson Karyopharm Therapeutics, Inc. Kineta, Inc. LG Life Science LTD. Ligand Pharmaceuticals, Inc. Medivir AB Merck & Co., Inc. Microbio Co., Ltd. Microbiotix, Inc. MultiCell Technologies, Inc. NeuroVive Pharmaceutical AB Novartis AG NovaTarg Therapeutics, Inc Ono Pharmaceutical Co., Ltd. Pfenex Inc. Pfizer Inc. PharmaEssentia Corporation Polaris Pharmaceuticals, Inc. Presidio Pharmaceuticals, Inc. Profectus BioSciences, Inc. Regulus Therapeutics Inc. REPLICor Inc. Rodos BioTarget GmbH Savoy Pharmaceuticals, Inc. SomaGenics, Inc. Sorrento Therapeutics, Inc. Spring Bank Pharmaceuticals, Inc. TaiGen Biotechnology Co., Ltd. TaiwanJ Pharmaceuticals Co., Ltd. TGV-Laboratories Therapix Biosciences Ltd. Therapure Biopharma Inc. Vakzine Projekt Management GmbH Vertex Pharmaceuticals Incorporated WhanIn Pharmaceutical Co., Ltd. Zylacta Corporation
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
posted by Reportstack @ 07:34
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home